Protein-free fed-batch culture of non-GS NS0 cell lines for production of recombinant antibodies

被引:26
作者
Burky, John E. [1 ]
Wesson, Mark C. [1 ]
Young, Amy [1 ]
Farnsworth, Sharyn [1 ]
Dionne, Ben [1 ]
Zhu, Ying [1 ]
Hartman, Taymar E. [1 ]
Qu, Limin [1 ]
Zhou, Weichang [1 ]
Saner, Paul W. [1 ]
机构
[1] PDL BioPharma Inc, Proc Sci & Engn, Fremont, CA 94555 USA
关键词
NS0 host cell line; fed-batch culture process platform; humanized antibodies; protein-free; lactate consumption;
D O I
10.1002/bit.21060
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Presented is a novel antibody production platform based on the fed-batch culture of recombinant NS0-derived cell lines. A standardized fed-batch culture process was developed for five non-GS NS0 cell lines using enriched and optimized protein-free, cholesterol-free, and chemically defined basal and feed media. The process performed reproducibly and scaled faithfully from the 2-L to the 100-L bioreactor scale achieving a volumetric productivity of > 120 mg/L per day. Fed-batch cultures for all five cell lines exhibited significant lactate consumption when the cells entered the stationary or death phase. Peak and final lactate concentrations were low relative to a previously developed fed-batch process (FBP). Such low lactate production and high lactate consumption rates were unanticipated considering the fed-batch culture basal medium has an unconventionally high initial glucose concentration of 15 g/L, and an overall glucose consumption in excess of 17 g/L. The potential of this process platform was further demonstrated through additional media optimization, which has resulted in a final antibody concentration of 2.64 +/- 0.19 g/L and volumetric productivity of > 200 mg/L per day in a 13-day FBP for one of the five cell production lines. Use of this standardized protein-free, cholesterol-free NS0 FBP platform enables consistency in development time and cost effectiveness for manufacturing of therapeutic antibodies.
引用
收藏
页码:281 / 293
页数:13
相关论文
共 42 条
[1]   HIGH-LEVEL EXPRESSION OF A RECOMBINANT ANTIBODY FROM MYELOMA CELLS USING A GLUTAMINE-SYNTHETASE GENE AS AN AMPLIFIABLE SELECTABLE MARKER [J].
BEBBINGTON, CR ;
RENNER, G ;
THOMSON, S ;
KING, D ;
ABRAMS, D ;
YARRANTON, GT .
BIO-TECHNOLOGY, 1992, 10 (02) :169-175
[2]  
BIBILA T, 1994, ANN NY ACAD SCI, V745, P277
[3]   IN PURSUIT OF THE OPTIMAL FED-BATCH PROCESS FOR MONOCLONAL-ANTIBODY PRODUCTION [J].
BIBILA, TA ;
ROBINSON, DK .
BIOTECHNOLOGY PROGRESS, 1995, 11 (01) :1-13
[4]   SELECTING AND DESIGNING CELL-LINES FOR IMPROVED PHYSIOLOGICAL-CHARACTERISTICS [J].
BIRCH, JR ;
BORASTON, RC ;
METCALFE, H ;
BROWN, ME ;
BEBBINGTON, CR ;
FIELD, RP .
CYTOTECHNOLOGY, 1994, 15 (1-3) :11-16
[5]   Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species [J].
Brand, KA ;
Hermfisse, U .
FASEB JOURNAL, 1997, 11 (05) :388-395
[6]  
Brooks G.A., 1985, CIRC RESP METAB CURR, P208
[7]   Intra- and extra-cellular lactate shuttles [J].
Brooks, GA .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2000, 32 (04) :790-799
[8]  
Cain SJ, 1998, BIOTECHNOL BIOENG, V58, P387, DOI 10.1002/(SICI)1097-0290(19980520)58:4<387::AID-BIT6>3.3.CO
[9]  
2-B
[10]   Therapeutic antibody expression technology [J].
Chadd, HE ;
Chamow, SM .
CURRENT OPINION IN BIOTECHNOLOGY, 2001, 12 (02) :188-194